Youe-Kong Shue

Title: The Innovative Contributions of Youe-Kong Shue

Introduction

Youe-Kong Shue is a prominent inventor based in Taipei, Taiwan. He has made significant strides in the field of cancer immunotherapy, focusing on innovative methods to enhance immune responses against cancer cells. His work is particularly relevant in the context of metastatic breast cancer, where effective treatment options are critically needed.

Latest Patents

Youe-Kong Shue holds a patent for a groundbreaking method of cancer immunotherapy. The patent, titled "Cancer immunotherapy by immune activation or immune modulation via Globo series antigens," outlines a method that involves administering vaccines against Globo series antigens, including Globo H, Stage-specific embryonic antigen 3 (SSEA3), and Stage-specific embryonic antigen 4 (SSEA4). Specifically, the method includes administering Globo H-KLH (OBI-822) to patients suffering from metastatic breast cancer. This innovative approach not only targets cancer cells but also identifies suitable candidates for immunotherapy, enhancing the potential for successful treatment outcomes.

Career Highlights

Throughout his career, Youe-Kong Shue has been associated with Obi Pharma Inc., where he has contributed to the development of novel therapeutic agents. His work has focused on creating monoclonal antibodies (mAbs) that specifically bind to Globo series antigens, which are crucial for developing targeted therapeutic and diagnostic regimens. His dedication to advancing cancer treatment has positioned him as a key figure in the field of immunotherapy.

Collaborations

Youe-Kong Shue has collaborated with notable colleagues, including Cheng-Der Tony Yu and Chen-Hsin Liang. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas, ultimately leading to advancements in cancer treatment.

Conclusion

Youe-Kong Shue's contributions to cancer immunotherapy exemplify the impact of innovative thinking in the medical field. His patent and ongoing work at Obi Pharma Inc. highlight the importance of targeted therapies in the fight against cancer. As research continues to evolve, the methods developed by Shue may pave the way for more effective treatments in the future.